- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07681310
GreenArt: Nutrikinetics and Bioavailability Studies
26 juin 2026 mis à jour par: Fytexia
Baccharis-type Propolis Extract, GreenArt: Nutrikinetics and Bioavailability Studies
The aim of this study is to investigate phenolic compounds from GreenArt, a baccharis-type propolis ingredient, bioavailability and nutrikinetics by measuring urinary excretion and metabolic profile over 48h by means of high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS).
The study follows a cross-over, double-blind, randomized and placebo control design on 10 healthy subjects.
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Intervention / Traitement
- Complément alimentaire: GreenArt D is a baccharis-type propolis powder extract containing phenolic compounds such as prenylated phenylpropanoids derived from hydroxycinnamic acids and flavonoids.
- Complément alimentaire: GreenArt 4D is a baccharis-type propolis powder extract containing phenolic compounds such as prenylated phenylpropanoids derived from hydroxycinnamic acids and flavonoids.
- Complément alimentaire: Placebo
Type d'étude
Interventionnel
Inscription (Estimé)
10
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Julien Cases, PhD
- Numéro de téléphone: +33467219098
- E-mail: jcases@biotexia.com
Lieux d'étude
-
-
Murcia
-
Guadalupe, Murcia, Espagne, 30107
- UCAM Universidad Católica San Antonio de Murcia
-
Contact:
- Linda H. Chung, PhD
- Numéro de téléphone: + 34 968 278 611
- E-mail: lhchung@ucam.edu
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Oui
La description
Inclusion Criteria:
- Provision of signed and dated informed consent form.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Male and female with 40% min. and 60% max. of each sex.
- Aged 25 to 69 years old
- BMI range (18.5 - 29.99)
- In good general health as evidenced by medical history
- Ability to take oral supplementation and be willing to adhere to the regimen
- Agreement to adhere to Lifestyle Considerations (controlled diet) throughout study duration
Exclusion Criteria:
- Current use of any medication or food supplement
- Antibiotic use less than 12 weeks before the study
- Pregnancy or lactation
- Known allergic reactions to components of the supplement, i.e., bee products (specially propolis) and known allergy (general)
- Metabolic disorders or any kind of disease
- Current smoker
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: GreenArt D
This arm receives 150 mg of GreenArt, a baccharis-type propolis phenolic extract
|
GreenArt D contains 150 mg of GreenArt
|
|
Expérimental: GreenArt 4D
This arm receives 600 mg of GreenArt, a baccharis-type propolis phenolic extract
|
GreenArt 4D contains 600 mg of GreenArt
|
|
Comparateur placebo: Placebo
This arm receives 150 mg of mix carriers of the GreenArt ingredient, a baccharis-type propolis phenolic extract
|
Placebo is composed of the carriers of GreenArt : gum arabic, sucrose and silicon dioxide mix.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in plasma area under the curve (AUC) of phenolic metabolites after acute ingestion of the supplement/placebo
Délai: Baseline (pre-ingestion) to 24 hour post-ingestion
|
Plasma samples will be collected in EDTA tubes in baseline before supplement/placebo intake (0h) and up to 24h according to the time frame.
Phenolic compounds metabolites in plasma will be identified and quantified by HPLC-MS.
Targeted metabolites are prenylated phenolic acids, phenolic acids and flavonoids derivatives.
For each identified and quantified metabolite the area under the curve (0-24 hour) in nmol/L-h is measured.
|
Baseline (pre-ingestion) to 24 hour post-ingestion
|
|
Change in plasma maximal concentration (Cmax) of phenolic metabolites after acute ingestion of the supplement/placebo
Délai: Baseline (pre-ingestion) and 0.5 hour, 1 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 24 hour post-ingestion
|
Plasma samples will be collected in EDTA tubes in baseline before supplement/placebo intake (0h) and up to 24h according to the time frame.
Phenolic compounds metabolites in plasma will be identified and quantified by HPLC-MS.
Targeted metabolites are prenylated phenolic acids, phenolic acids and flavonoids derivatives.
For each identified and quantified metabolite the maximal concentration in nmol/L is measured.
|
Baseline (pre-ingestion) and 0.5 hour, 1 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 24 hour post-ingestion
|
|
Change in plasma time to reach maximal concentration (Tmax) of phenolic metabolites after acute ingestion of the supplement/placebo
Délai: Baseline (pre-ingestion) and 0.5 hour, 1 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 24 hour post-ingestion
|
Plasma samples will be collected in EDTA tubes in baseline before supplement/placebo intake (0h) and up to 24h according to the time frame.
Phenolic compounds metabolites in plasma will be identified and quantified by HPLC-MS.
Targeted metabolites are prenylated phenolic acids, phenolic acids, and flavonoids derivatives.
For each identified and quantified metabolite the time to reach maximum concentration in hour is measured.
|
Baseline (pre-ingestion) and 0.5 hour, 1 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 24 hour post-ingestion
|
|
Change in urine area under the curve (AUC) phenolic metabolites excretion after acute ingestion of the supplement/placebo
Délai: Baseline (pre-ingestion) to 48 hour post-ingestion
|
Urine samples will be collected in baseline (0h pre-ingestion) and up to 48h according to the time frame.
Phenolic compounds metabolites in urine will be identified and quantified by HPLC-MS.
Targeted metabolites are prenylated phenolic acids, phenolic acids and flavonoids derivatives.
For each identified and quantified metabolite the area under the curve (0-24 hour) in nmol/L-h is measured.
|
Baseline (pre-ingestion) to 48 hour post-ingestion
|
|
Change in urine maximal concentration (Cmax) phenolic metabolites excretion after acute ingestion of the supplement/placebo
Délai: Baseline (pre-ingestion) and 0 hour - 3 hour, 3 hour - 6 hour, 6 hour - 10 hour, 10 hour - 14 hour, 14 hour - 24 hour, 24 hour - 36 hour and 36 hour - 48 hour post-ingestion
|
Urine samples will be collected in baseline (0h pre-ingestion) and up to 48h according to the time frame.
Phenolic compounds metabolites in urine will be identified and quantified by HPLC-MS.
Targeted metabolites are penylated phenolic acids, phenolic acids and flavonoids derivatives.
For each identified and quantified metabolite the maximal concentration in nmol/L is measured.
|
Baseline (pre-ingestion) and 0 hour - 3 hour, 3 hour - 6 hour, 6 hour - 10 hour, 10 hour - 14 hour, 14 hour - 24 hour, 24 hour - 36 hour and 36 hour - 48 hour post-ingestion
|
|
Change in urine time to reach maximal concentration (Tmax) phenolic metabolites excretion after acute ingestion of the supplement/placebo
Délai: Baseline (pre-ingestion) and 0 hour - 3 hour, 3 hour - 6 hour, 6 hour - 10 hour, 10 hour - 14 hour, 14 hour - 24 hour, 24 hour - 36 hour and 36 hour - 48 hour post-ingestion
|
Urine samples will be collected in baseline (0h pre-ingestion) and up to 48h according to the time frame.
Phenolic compounds metabolites in urine will be identified and quantified by HPLC-MS.
Targeted metabolites are prenylated phenolic acids, phenolic acids and flavonoids derivatives.
For each identified and quantified metabolite the time to reach maximum concentration in hour is measured.
|
Baseline (pre-ingestion) and 0 hour - 3 hour, 3 hour - 6 hour, 6 hour - 10 hour, 10 hour - 14 hour, 14 hour - 24 hour, 24 hour - 36 hour and 36 hour - 48 hour post-ingestion
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
1 juin 2026
Achèvement primaire (Estimé)
1 juillet 2026
Achèvement de l'étude (Estimé)
1 juillet 2026
Dates d'inscription aux études
Première soumission
26 juin 2026
Première soumission répondant aux critères de contrôle qualité
26 juin 2026
Première publication (Réel)
2 juillet 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
2 juillet 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
26 juin 2026
Dernière vérification
1 juin 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- GREENKBA
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .